Is Pola-R-CHP a suitable standard for all or should the lack of survival benefit and differential subgroup responses give pause in treating all patients who qualify?

Under the new leadership of Marty Makary, the FDA should focus more attention on the critical role of real-world clinical data — such as from health insurance databases — in the ongoing assessment of ...

During Neuralink’s summer update on the trial, they showed the moment one participant was able to move a cursor with his ...

New clinical trials are advancing in hard-to-treat cancers, offering targeted and less toxic options for patients with ...

Marwan G. Fakih, MD, discusses the top takeaways from using combination treatment in metastatic colorectal cancer.

Patient-reported outcomes could have a prognostic and predictive impact on care for multiple myeloma.A retrospective analysis ...

Both 6-month trials were randomized, controlled studies that evaluated PER-001 delivered in a slow-release, dissolvable ...

Five individuals (3.3%) experienced peak aminotransferase levels greater than five times the ULN, and two (1.3%) had ...

New stem cell therapy offers hope for type 1 diabetes, freeing patients from insulin. Learn why diverse clinical trial ...